Posted by Michael Wonder on 16 Dec 2024
Celltrion receives positive CHMP opinion for three biosimilars in the European Union
15 December 2024 - The CHMP adopts positive opinions for Celltrion’s three biosimilar candidates – Eydenzelt (aflibercept), Stoboclo and Osenvelt (denosumab), and Avtozma (tocilizumab).
Celltrion today announced that the CHMP of the EMA has adopted positive opinions and recommended marketing authorisations for three biosimilar candidates: Eydenzelt (CT-P42, aflibercept), Stoboclo and Osenvelt (CT-P41, denosumab), and Avtozma (CT-P47, tocilizumab).
